Agilent Technologies (A) Scheduled to Post Quarterly Earnings on Tuesday – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Agilent Technologies logo Agilent Technologies (NYSE:A – Get Rating) is set to announce its earnings results after the market closes on Tuesday, August 16th. Analysts expect the company to announce earnings of $1.21 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Agilent Technologies (NYSE:A – Get Rating) last issued its quarterly earnings results on Tuesday, May 24th. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.02. The business had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.62 billion. Agilent Technologies had a return on equity of 27.42% and a net margin of 19.35%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.97 earnings per share. On average, analysts expect Agilent Technologies to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Agilent Technologies Trading Down 0.8 %

Shares of A stock opened at $132.52 on Tuesday. The company has a current ratio of 2.01, a quick ratio of 1.49 and a debt-to-equity ratio of 0.53. The stock has a market cap of $39.58 billion, a P/E ratio of 31.93, a price-to-earnings-growth ratio of 2.74 and a beta of 1.06. The stock has a 50 day simple moving average of $122.73 and a 200 day simple moving average of $127.65. Agilent Technologies has a 1 year low of $112.52 and a 1 year high of $179.57.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 27th. Investors of record on Tuesday, July 5th were paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Friday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 20.24%.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, VP Jacob Thaysen sold 5,879 shares of the company’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $127.43, for a total transaction of $749,160.97. Following the sale, the vice president now owns 88,737 shares of the company’s stock, valued at $11,307,755.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Agilent Technologies news, VP Jacob Thaysen sold 5,879 shares of the company’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $127.43, for a total transaction of $749,160.97. Following the sale, the vice president now owns 88,737 shares of the company’s stock, valued at $11,307,755.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padraig Mcdonnell sold 1,000 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $118.62, for a total transaction of $118,620.00. Following the transaction, the vice president now directly owns 17,826 shares in the company, valued at approximately $2,114,520.12. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Agilent Technologies

Institutional investors and hedge funds have recently made changes to their positions in the stock. Neuberger Berman Group LLC lifted its position in Agilent Technologies by 8.7% in the 1st quarter. Neuberger Berman Group LLC now owns 84,268 shares of the medical research company’s stock valued at $11,172,000 after acquiring an additional 6,779 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Agilent Technologies by 22.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 324,138 shares of the medical research company’s stock valued at $43,235,000 after acquiring an additional 59,762 shares in the last quarter. Toroso Investments LLC lifted its position in Agilent Technologies by 13.6% in the 1st quarter. Toroso Investments LLC now owns 6,182 shares of the medical research company’s stock valued at $818,000 after acquiring an additional 739 shares in the last quarter. Orion Portfolio Solutions LLC lifted its position in Agilent Technologies by 12.3% in the 1st quarter. Orion Portfolio Solutions LLC now owns 2,880 shares of the medical research company’s stock valued at $381,000 after acquiring an additional 315 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Agilent Technologies by 24.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 408,780 shares of the medical research company’s stock valued at $54,094,000 after acquiring an additional 80,848 shares in the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on A. KeyCorp cut their target price on Agilent Technologies from $195.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, June 2nd. Wells Fargo & Company cut their target price on Agilent Technologies from $160.00 to $130.00 and set an “equal weight” rating for the company in a research note on Monday, April 25th. StockNews.com upgraded Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 3rd. UBS Group began coverage on Agilent Technologies in a research note on Wednesday, July 20th. They set a “buy” rating and a $139.00 target price for the company. Finally, Citigroup cut Agilent Technologies from a “buy” rating to a “neutral” rating and cut their target price for the stock from $175.00 to $140.00 in a research note on Friday, July 8th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $152.75.

About Agilent Technologies

(Get Rating)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Recommended Stories

Earnings History for Agilent Technologies (NYSE:A)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilent Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Agilent Technologies wasn’t on the list.
While Agilent Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source